KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Equivalents (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Cash & Equivalents for 7 consecutive years, with $53.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash & Equivalents rose 58.66% year-over-year to $53.0 million, compared with a TTM value of $53.0 million through Jun 2025, up 58.66%, and an annual FY2024 reading of $83.4 million, up 70.71% over the prior year.
  • Cash & Equivalents was $53.0 million for Q2 2025 at Aurinia Pharmaceuticals, down from $66.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $231.9 million in Q4 2021 and bottomed at $33.4 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $90.9 million, with a median of $82.6 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 59.39% in 2022, then soared 70.71% in 2024.
  • Year by year, Cash & Equivalents stood at $231.9 million in 2021, then plummeted by 59.39% to $94.2 million in 2022, then tumbled by 48.1% to $48.9 million in 2023, then skyrocketed by 70.71% to $83.4 million in 2024, then crashed by 36.47% to $53.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for AUPH at $53.0 million in Q2 2025, $66.4 million in Q1 2025, and $83.4 million in Q4 2024.